» Articles » PMID: 177440

Acute Administration of 25-hydroxycholecalciferol in Man

Overview
Specialty Endocrinology
Date 1976 Feb 1
PMID 177440
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Serum 25-hydroxyvitamin D responses to oral doses of 25-hydroxycholecalciferol were measured in healthy volunteers. Peak serum 25-hydroxyvitamin D levels occurred 4 to 8 hours after doses of 1.5, 5, and 10 mug per kg of body weight. The mean increments above baseline serum 25-hydroxyvitamin D concentrations at 4 hours were linear over this dose range. Following a single oral dose, serum 25-hydroxyvitamin D levels fell to 33% of their peak values after one week. The serum 25-hydroxyvitamin D responses measured by competitive protein-binding radioassay were similar to the serum 3H responses exhibited by three volunteers who received simultaneous oral doses of 3H 25-hydroxycholecalciferol and 14C-cholecalciferol. The appearance of 14C in plasma was slower and less marked compared with 3H, probably reflecting a more rapid plasma clearance of the 14C-cholecalciferol. The disappearance of 25-hydroxycholecalciferol from the circulation of two volunteers following acute intravenous delivery of 1.0 mg of 25-hydroxycholecalciferol was multiphasic over 10 days. 60% of the dose administered remained in the circulation 24 hours after the dose. When analyzed several days after single 10 mug/kg oral doses of 25-hydroxycholecalciferol to 4 volunteers, the mean rate of decline to total serum 25-hydroxycholecalciferol was slow (t 1/2 = 22 days). When baseline serum 25-hydroxyvitamin D levels were subtracted, however, the apparent serum half-life of administered 25-hydroxycholecalciferol was 12 days, similar to that reported after tracer doses of 3H-25-hydroxycholecalciferol. The rapid and predictable serum 25-hydroxyvitamin D increases following the oral administration of 25-hydroxycholecalciferol suggest its possible therapeutic advantages compared with vitamin D administration.

Citing Articles

Determinants and Effects of Vitamin D Supplementation in Postmenopausal Women: A Systematic Review.

Hassanein M, Huri H, Baig K, Abduelkarem A Nutrients. 2023; 15(3).

PMID: 36771392 PMC: 9919965. DOI: 10.3390/nu15030685.


Vitamin D deficiency in British South Asians, a persistent but avoidable problem associated with many health risks (including rickets, T2DM, CVD, COVID-19 and pregnancy complications): the case for correcting this deficiency.

Boucher B Endocr Connect. 2022; 11(12).

PMID: 36149836 PMC: 9641767. DOI: 10.1530/EC-22-0234.


Validation of the 24,25-dihydroxyvitamin D to 25-hydroxyvitamin D ratio as a biomarker of 25-hydroxyvitamin D clearance.

Hsu S, Zelnick L, Lin Y, Best C, Kestenbaum B, Thummel K J Steroid Biochem Mol Biol. 2021; 217:106047.

PMID: 34954017 PMC: 8837693. DOI: 10.1016/j.jsbmb.2021.106047.


Vitamin D kinetics in nonpregnant and pregnant women after a single oral dose of trideuterated vitamin D.

Best C, Sherwood R, Novotny J, Zhang S, Pressman E, OBrien K J Steroid Biochem Mol Biol. 2021; 216:106034.

PMID: 34843870 PMC: 8749867. DOI: 10.1016/j.jsbmb.2021.106034.


Safety of calcidiol monohydrate produced by chemical synthesis as a novel food pursuant to Regulation (EU) 2015/2283.

Turck D, Castenmiller J, de Henauw S, Hirsch-Ernst K, Kearney J, Maciuk A EFSA J. 2021; 19(7):e06660.

PMID: 34249156 PMC: 8247530. DOI: 10.2903/j.efsa.2021.6660.